Eli Lilly And Company
—- Market cap
- —
- Debt
- +$42.50B
- Cash
- −$7.27B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: LLY stock price vs HWM: inconclusive — current versus $1.42K implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at HWM's multiple
Implied fair value · at LLY's multiple
Needs LLY P/E.
Snapshot Sep 11, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 97% equity / 3% debt · EV / Revenue 11.38x · EV proxy / EBITDA proxy 40.31x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ELI LILLY AND COMPANY · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
HOWMET AEROSPACE INC. · implied price per share
Bear
$35.51
Base
$44.03
Bull
$55.79
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Pfizer Inc.
LLY vs PFE
Merck & Co., Inc.
LLY vs MRK
Johnson & Johnson
LLY vs JNJ
AbbVie Inc.
LLY vs ABBV
Amgen Inc.
LLY vs AMGN
Bristol-Myers Squibb Company
LLY vs BMY
RTX Corp
LLY vs RTX
LOCKHEED MARTIN CORP
LLY vs LMT
NORTHROP GRUMMAN CORP /DE/
LLY vs NOC
BOEING CO
LLY vs BA
GENERAL DYNAMICS CORP
LLY vs GD
HUNTINGTON INGALLS INDUSTRIES, INC.
LLY vs HII
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe LLY can sustain its 44.7% revenue growth and 31.7% net margin, then hold or add on weakness because the P/E-implied valuation suggests meaningful upside relative to the current price.
LLY's current price of $1,191.94 is well below the P/E-implied value of $1,792.20, suggesting a 50.4% upside on that framework. However, relative to HWM, LLY trades at a lower P/E but a higher P/S and EV/Revenue, so the valuation signal is inconsistent across methods.
Supporting Metrics